



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## Anti-Amyloid beta A4 protein [LY2062430 (Solanezumab, hu266)] Standard Size Ab04185-3.0

**Isotype and Format:** Mouse IgG2b, Kappa

**Clone Number:** LY2062430 (Solanezumab, hu266)

**Alternative Name(s) of Target:** APP; A $\beta$  peptide; Abeta; A-beta; A $\beta$ ; A $\beta$ 42; amyloid beta peptide; Alzheimer disease amyloid protein; Beta-amyloid precursor protein; Protease nexin-II; humanized m266.2

**UniProt Accession Number of Target Protein:** P05067

**Published Application(s):** therapeutic, ELISA

**Published Species Reactivity:** Human

**Immunogen:** The parental mouse antibody 266 was generated by immunization of mice with a peptide composed of residues 13-28 of human A $\beta$  peptide. The original humanized version of the antibody was generated by grafting CDRs of the mouse antibody onto human framework regions.

**Specificity:** This antibody recognizes amino acids 13-28 of amyloid beta and only recognized soluble form of the amyloid beta peptide. It functions as a cell surface receptor and performs physiological functions on the surface of neurons relevant to neurite growth, neuronal adhesion and axonogenesis. Interaction between APP molecules on neighboring cells promotes synaptogenesis.

**Application Notes:** The human IgG1 version of this antibody binds amyloid beta peptide A $\beta$ 1-42 with a binding affinity of  $K_d = 4\text{pM}$  in an in vitro BIAcore assay. The binding characterization of this antibody towards A $\beta$ 1-42-BSA conjugate was done using ELISA (US8591894). A study in patients with Alzheimer's disease (AD) suggested that a single dose of solanezumab was generally well tolerated, except that mild self-limited symptoms consistent with infusion reactions occurred in few patients when higher doses are given. A dose-dependent change in plasma and CSF Abeta was also observed (PMID: 20375655). The original mouse antibody 266 slowed A $\beta$  accumulation in the brain but failed to deplete A $\beta$  plaques in animal studies (PMID: 11438712). This humanized antibody is likely to have impeded the efflux of soluble A $\beta$  from the brain in patients owing to the formation of A $\beta$ -antibody complexes in the brain interstitial fluid and cerebrospinal fluid, as suggested from animal studies (PMID: 24638135). Phase 1 and 2 studies of solanezumab revealed evidence of target engagement by dose-dependent increases in plasma and CSF total A $\beta$  (PMID: 20375655; 22672770). In the phase 2 study of mild to moderate AD, 12 weeks of solanezumab treatment yielded a dose-dependent increase in CSF-free A $\beta$ 42, suggesting a shift in equilibria sufficient to mobilize A $\beta$ 42 from plaques (PMID: 22672770). In the first phase III studies, solanezumab did not demonstrate significant benefit for the primary outcomes in either study but showed a

favorable safety profile (PMID: 26238576).

**Antibody First Published in:** Siemers et al. Safety and changes in plasma and cerebrospinal fluid amyloid beta after a single administration of an amyloid beta monoclonal antibody in subjects with Alzheimer disease. Clin Neuropharmacol. 2010 Mar-Apr;33(2):67-73. [PMID:20375655](#)

**Note on publication:** This study evaluates the safety and tolerance of solanezumab after single administration in patients with Alzheimer's disease.

## Product Form

**Size:** 100 µg Purified antibody.

**Purification:** Protein A affinity purified

**Supplied In:** PBS with 0.02% Proclin 300.

**Storage Recommendation:** Store at 4°C for up to 3 months. For longer storage, aliquot and store at -20°C.

**Concentration:** 1 mg/ml.

Important note - This product is for research use only. It is not intended for use in therapeutic or diagnostic procedures for humans or animals.